Marker Therapeutics Q2 2024 GAAP EPS $(0.25) Beats $(0.43) Estimate, Sales $1.17M Up From $762.66K YoY
Portfolio Pulse from Benzinga Newsdesk
Marker Therapeutics (NASDAQ:MRKR) reported Q2 2024 GAAP EPS of $(0.25), beating the analyst estimate of $(0.43) by 41.86%. The company also reported sales of $1.17 million, a 53.28% increase from the same period last year.
August 14, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Marker Therapeutics reported better-than-expected Q2 2024 GAAP EPS of $(0.25), beating the analyst estimate of $(0.43) by 41.86%. Sales increased by 53.28% YoY to $1.17 million.
The better-than-expected EPS and significant YoY sales growth are positive indicators for Marker Therapeutics. This could lead to a short-term increase in the stock price as investors react to the strong financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100